Humanin vs Teriparatide
A side-by-side research comparison of Humanin and Teriparatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | Teriparatide |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | Teriparatide (PTH 1-34) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved drug (prescription) |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength. |
| Molecular weight | 2,687 Da | 4117.8 Da |
| Half-life | 4-6 hours | ~1 hour (subcutaneous) |
| Bioavailability | Moderate (SubQ) | ~95% subcutaneous |
| Typical dose | 1-5 mg | 20 mcg once daily (medical) |
| Frequency | 3-5x per week | Once daily |
| Route | Subcutaneous | Subcutaneous injection |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Teriparatide reported benefits
- Actively builds new bone
- Increases bone mineral density
- Reduces fracture risk (medical)
- Supports bone healing
Related comparisons
Research and educational reference only. Not medical advice.